JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy

BACKGROUND: T cell engaging therapies, like chimeric antigen receptor T cells and T cell bispecific antibodies (TCBs), efficiently redirect T cells towards tumor cells, facilitating the formation of a cytotoxic synapse and resulting in subsequent tumor cell killing, a process that is accompanied by...

Descripción completa

Detalles Bibliográficos
Autores principales: Leclercq, Gabrielle, Haegel, Hélène, Toso, Alberto, Zimmermann, Tina, Green, Luke, Steinhoff, Nathalie, Sam, Johannes, Pulko, Vesna, Schneider, Anneliese, Giusti, Anna Maria, Challier, John, Freimoser-Grundschober, Anne, Larivière, Laurent, Odermatt, Alex, Stern, Martin, Umana, Pablo, Bacac, Marina, Klein, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785208/
https://www.ncbi.nlm.nih.gov/pubmed/35064010
http://dx.doi.org/10.1136/jitc-2021-003766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785208/
https://www.ncbi.nlm.nih.gov/pubmed/35064010
http://dx.doi.org/10.1136/jitc-2021-003766

Ejemplares similares